Small pharma companies tend to have one product or technology that could make them a highly successful investment. In some cases, there is a well advanced second treatment using different life sciences technology.
This pharma company has a treatment to prevent serious infections that has already had highly positive phase 2b clinical study results. The next step will be the design of a phase 3 clinical study.
There is also a second, acquired technology that could move to a phase 3 clinical study next year. This is another antimicrobial drug to prevent serious infections.
The share price did rise on the back of positive news, but it has fallen from its recent high and is around one-half of the analyst target share prices. Cash should last until the second half of 2022.
There is ...